venetoclax is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
venetoclax is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
from FDA,2022.06
Venetoclax is the only approved selective inhibitor of Bcl-2 in the world. By bi···【more】
Release date:2024-08-13Recommended:112